Login to Your Account



Turning Away from RA

Syk ’Em: Rigel Taking On ITP; Amgen, GSK Game to Change?

By Randy Osborne
Staff Writer

Friday, September 6, 2013
Not surprisingly, Rigel Pharmaceuticals Inc. has decided not to pursue the oral spleen tyrosine kinase (Syk) inhibitor fostamatinib in rheumatoid arthritis (RA) after Astrazeneca plc, unhappy with trial data, returned the rights to the compound last month.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription